STOCK TITAN

Lifecore Biomedical Inc - LFCR STOCK NEWS

Welcome to our dedicated news page for Lifecore Biomedical (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lifecore Biomedical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lifecore Biomedical's position in the market.

Rhea-AI Summary
Lifecore Biomedical, Inc. receives notice of non-compliance with Nasdaq listing rule
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
SHL Medical enters co-marketing partnership with Lifecore Biomedical
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
partnership
-
Rhea-AI Summary
Lifecore Biomedical provides update on delayed filings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Rhea-AI Summary
Lifecore Biomedical reports Q4 and FY 2023 results. Q4 revenues increased 12.2% YoY. Net loss from continuing operations in Q4 was $33.8 million. Lifecore segment adjusted EBITDA decreased to $6.1 million. FY 2023 revenues decreased 7.2% YoY. Lifecore segment adjusted EBITDA decreased to $14.7 million. Cash used in operations for FY 2023 was $34.5 million. Cash and cash equivalents as of May 28, 2023, were $19.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.8%
Tags
-
Rhea-AI Summary
Lifecore Biomedical, Inc. to host conference call on August 31 to discuss fiscal 2023 Q4 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Summary
Lifecore Biomedical received a notice from Nasdaq for non-compliance with filing its Annual Report. No immediate effect on stock listing or trading. The company has 60 days to submit a plan to regain compliance. If accepted, they have up to 180 days to file the report.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50.19%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Lifecore Biomedical Inc

Nasdaq:LFCR

LFCR Rankings

LFCR Stock Data

185.11M
17.93M
4.53%
74.74%
5.85%
Plastics Material and Resin Manufacturing
Manufacturing
Link
US
Santa Clara

About LFCR

landec corporation (nasdaq:lndc) is a leading innovator of diversified health and wellness solutions within the packaged food and biomaterial markets. apio, landec's food business, is the leader in branded, packaged fresh vegetables in north america, utilizing its proprietary breatheway® packaging technology to naturally extend the shelf life of fresh produce. apio combines this technology with the capabilities of a large national fresh produce supplier to offer healthy fresh vegetable products under the eat smart® brand to consumers through club and retail grocery stores. lifecore biomedical, landec's biomaterial business, is a fully integrated contract development and manufacturing organization (cdmo) that offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for fda regulated medical devices and drugs to customers for applications in a wide array of markets including ophthalmic, orthopedic and oncology. for more information abo